A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer

PURPOSE: Germ cell tumors (GCTs) are cured with therapy based on cisplatin, although a clinically significant number of patients are refractory and die of progressive disease. Based on preclinical studies indicating that refractory testicular GCTs are hypersensitive to hypomethylating agents (HMAs),...

Descripción completa

Detalles Bibliográficos
Autores principales: Albany, Costantine, Fazal, Zeeshan, Singh, Ratnakar, Bikorimana, Emmanuel, Adra, Nabil, Hanna, Nasser H., Einhorn, Lawrence H., Perkins, Susan M., Sandusky, George E., Christensen, Brock C., Keer, Harold, Fang, Fang, Nephew, Kenneth P., Spinella, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826483/
https://www.ncbi.nlm.nih.gov/pubmed/33135391
http://dx.doi.org/10.1002/cam4.3583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826483/
https://www.ncbi.nlm.nih.gov/pubmed/33135391
http://dx.doi.org/10.1002/cam4.3583

Ejemplares similares